LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 179

Search options

  1. Article ; Online: Reply to 'Physician burnout: let's avoid unsubstantiated claims'.

    Banerjee, Susana

    Nature reviews. Clinical oncology

    2019  Volume 16, Issue 2, Page(s) 137

    MeSH term(s) Burnout, Psychological ; Humans
    Language English
    Publishing date 2019-01-18
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-018-0151-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen-Reply.

    Giannone, Gaia / McNeish, Iain A / Banerjee, Susana

    JAMA oncology

    2023  Volume 9, Issue 11, Page(s) 1586–1587

    MeSH term(s) Humans ; Pyrimidines ; Paclitaxel/adverse effects ; Benzamides ; Biomarkers ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances vistusertib (0BSC3P4H5X) ; Pyrimidines ; Paclitaxel (P88XT4IS4D) ; Benzamides ; Biomarkers
    Language English
    Publishing date 2023-09-07
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.3401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: New therapies for clear cell ovarian carcinoma.

    Stewart, James / Cunningham, Niamh / Banerjee, Susana

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2023  Volume 33, Issue 3, Page(s) 385–393

    Abstract: Ovarian clear cell carcinoma is a rare subtype of epithelial ovarian cancer with unique clinicopathological features. The most common genetic aberration observed is loss of ... ...

    Abstract Ovarian clear cell carcinoma is a rare subtype of epithelial ovarian cancer with unique clinicopathological features. The most common genetic aberration observed is loss of function
    MeSH term(s) Female ; Humans ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/therapy ; Adenocarcinoma, Clear Cell/genetics ; Adenocarcinoma, Clear Cell/therapy ; Mutation ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/therapy
    Language English
    Publishing date 2023-03-06
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2022-003704
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Special issue: Emerging microbial technologies for wastewater treatment.

    Shah, Maulin P / Banerjee, Rajarshi / Rodríguez-Couto, Susana

    Journal of basic microbiology

    2022  Volume 62, Issue 3-4, Page(s) 199–200

    MeSH term(s) Waste Water ; Water Purification
    Chemical Substances Waste Water
    Language English
    Publishing date 2022-03-21
    Publishing country Germany
    Document type Editorial
    ZDB-ID 632513-0
    ISSN 1521-4028 ; 0233-111X
    ISSN (online) 1521-4028
    ISSN 0233-111X
    DOI 10.1002/jobm.202200133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Bevacizumab in cervical cancer: a step forward for survival.

    Banerjee, Susana

    Lancet (London, England)

    2017  Volume 390, Issue 10103, Page(s) 1626–1628

    MeSH term(s) Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab ; Disease-Free Survival ; Female ; Humans ; Uterine Cervical Neoplasms
    Chemical Substances Angiogenesis Inhibitors ; Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2017-07-27
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(17)31965-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: JC Polyomavirus T-antigen protein expression and the risk of colorectal cancer: Systematic review and meta-analysis of case-control studies.

    Kimla, Lenka J / Clark, Taane G / Banerjee, Sri / Campino, Susana

    PloS one

    2023  Volume 18, Issue 3, Page(s) e0283642

    Abstract: JC Polyomavirus (JCV) is a human polyomavirus encoding T-antigen protein, which is implicated in carcinogenesis. JCV is prevalent in the upper and lower gastrointestinal track. Several studies have reported JCV associations with the risk of developing ... ...

    Abstract JC Polyomavirus (JCV) is a human polyomavirus encoding T-antigen protein, which is implicated in carcinogenesis. JCV is prevalent in the upper and lower gastrointestinal track. Several studies have reported JCV associations with the risk of developing colorectal cancer (CRC), however, these findings remain controversial. Since JCV DNA may be present in healthy tissues as well as transformed tissues, JCV T-antigen expression could be a more useful measure of JCV's association with cancer development. The aim of this study is to conduct a meta-analysis of case-control studies to investigate if there is a significant association between JCV T-antigen protein expression and risk of CRC. A systematic review was performed to identify studies reporting JCV DNA prevalence in CRC and JCV T-antigen expression. The strength of the association was estimated by odds ratios (ORs). Five (of 66) studies satisfied analysis inclusion criteria, and spanned years 1999 to 2022. Random effects meta-analysis of CRC cases versus controls showed an 11-fold increased risk of CRC development in JCV DNA positive samples with JCV T-antigen expression versus normal tissues (OR 10.95; 95% CI: 2.48-48.24; P = 0.0016). The results of this meta-analysis of JCV infection followed by JCV T-antigen protein expression for the risk of CRC support the argument that JCV infection significantly increases the risk of colorectal cancer in tissues where the JCV T-antigen protein is expressed. Further research with JCV T-antigen expression in relation to CRC development is needed.
    MeSH term(s) Humans ; Colorectal Neoplasms/genetics ; JC Virus/genetics ; JC Virus/metabolism ; Antigens, Viral, Tumor ; Odds Ratio ; Case-Control Studies ; DNA, Viral/genetics ; Polyomavirus Infections/epidemiology
    Chemical Substances Antigens, Viral, Tumor ; DNA, Viral
    Language English
    Publishing date 2023-03-31
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0283642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: JC Polyomavirus T-antigen protein expression and the risk of colorectal cancer

    Lenka J Kimla / Taane G Clark / Sri Banerjee / Susana Campino

    PLoS ONE, Vol 18, Iss 3, p e

    Systematic review and meta-analysis of case-control studies.

    2023  Volume 0283642

    Abstract: JC Polyomavirus (JCV) is a human polyomavirus encoding T-antigen protein, which is implicated in carcinogenesis. JCV is prevalent in the upper and lower gastrointestinal track. Several studies have reported JCV associations with the risk of developing ... ...

    Abstract JC Polyomavirus (JCV) is a human polyomavirus encoding T-antigen protein, which is implicated in carcinogenesis. JCV is prevalent in the upper and lower gastrointestinal track. Several studies have reported JCV associations with the risk of developing colorectal cancer (CRC), however, these findings remain controversial. Since JCV DNA may be present in healthy tissues as well as transformed tissues, JCV T-antigen expression could be a more useful measure of JCV's association with cancer development. The aim of this study is to conduct a meta-analysis of case-control studies to investigate if there is a significant association between JCV T-antigen protein expression and risk of CRC. A systematic review was performed to identify studies reporting JCV DNA prevalence in CRC and JCV T-antigen expression. The strength of the association was estimated by odds ratios (ORs). Five (of 66) studies satisfied analysis inclusion criteria, and spanned years 1999 to 2022. Random effects meta-analysis of CRC cases versus controls showed an 11-fold increased risk of CRC development in JCV DNA positive samples with JCV T-antigen expression versus normal tissues (OR 10.95; 95% CI: 2.48-48.24; P = 0.0016). The results of this meta-analysis of JCV infection followed by JCV T-antigen protein expression for the risk of CRC support the argument that JCV infection significantly increases the risk of colorectal cancer in tissues where the JCV T-antigen protein is expressed. Further research with JCV T-antigen expression in relation to CRC development is needed.
    Keywords Medicine ; R ; Science ; Q
    Subject code 570
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: First-line PARP inhibition in ovarian cancer - standard of care for all?

    Banerjee, Susana N / Lord, Christopher J

    Nature reviews. Clinical oncology

    2019  Volume 17, Issue 3, Page(s) 136–137

    MeSH term(s) Antineoplastic Agents/therapeutic use ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Clinical Trials as Topic ; Female ; Humans ; Mutation ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Progression-Free Survival ; Standard of Care
    Chemical Substances Antineoplastic Agents ; BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2019-08-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-020-0335-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Let's address burnout in oncologists and reimagine the way we work.

    Murali, Krithika / Banerjee, Susana

    Nature reviews. Clinical oncology

    2018  Volume 16, Issue 1, Page(s) 1–2

    MeSH term(s) Burnout, Professional ; Burnout, Psychological ; Humans ; Oncologists
    Language English
    Publishing date 2018-09-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-018-0097-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Recent advancements of antiangiogenic combination therapies in ovarian cancer.

    An, Daniel / Banerjee, Susana / Lee, Jung-Min

    Cancer treatment reviews

    2021  Volume 98, Page(s) 102224

    Abstract: Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly ... ...

    Abstract Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly used therapeutics have been identified, expanding the potential of identifying unique drug combinations and indicating new directions for improving clinical outcomes. Here, we review the mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer, as well as the interactions it exhibits with the immune and DNA damage response pathways. We discuss results from clinical trials examining the combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors are also discussed, as well as several ongoing trials.
    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Animals ; Antineoplastic Combined Chemotherapy Protocols ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Molecular Targeted Therapy ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/pathology ; Ovarian Neoplasms/blood supply ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
    Chemical Substances Angiogenesis Inhibitors ; Immune Checkpoint Inhibitors ; Poly(ADP-ribose) Polymerase Inhibitors
    Language English
    Publishing date 2021-05-19
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2021.102224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top